Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

University of Colorado, Denver500 enrolled

Overview

The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.

To identify baseline and treatment-related somatic changes in the tumor tissue from patients with lung and other thoracic cancers. To estimate the proportion of patients that subsequent therapy is altered based on the information acquired from such biopsies.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Lung Neoplasms

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies 2. Aged 18 years or older 3. Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis. 4. Patients must have the ability to understand and willingness to sign an informed consent document. Exclusion Criteria: \-

Locations (1)

University of Colorado Cancer Center

Aurora, Colorado, United States

RECRUITING

Outcomes

Primary Outcomes

To identify baseline and treatment-related somatic changes in the tumor tissue from patients with lung and other thoracic cancers.

Time frame: To be determined upon funding

Secondary Outcomes

To estimate the proportion of patients that subsequent therapy is altered based on the information acquired from such biopsies

Time frame: To be determined upon funding

Central Contacts

Brandi Kubala

CONTACT

303-724-1657 brandi.kubala@cuanschutz.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.